Sequoia Financial Advisors LLC acquired a new stake in Sanofi (NYSE:SNY) during the second quarter, Holdings Channel reports. The fund acquired 7,066 shares of the company’s stock, valued at approximately $296,000.
Other institutional investors have also recently bought and sold shares of the company. Pacad Investment Ltd. purchased a new position in Sanofi during the first quarter valued at $402,000. BlackRock Institutional Trust Company N.A. bought a new position in Sanofi during the first quarter valued at approximately $175,000. JPMorgan Chase & Co. boosted its position in Sanofi by 14.0% in the first quarter. JPMorgan Chase & Co. now owns 2,220,531 shares of the company’s stock valued at $89,178,000 after buying an additional 272,379 shares in the last quarter. Carnick & Kubik LLC boosted its position in Sanofi by 8.7% in the first quarter. Carnick & Kubik LLC now owns 11,681 shares of the company’s stock valued at $469,000 after buying an additional 930 shares in the last quarter. Finally, BB&T Securities LLC boosted its position in Sanofi by 21.4% in the first quarter. BB&T Securities LLC now owns 188,094 shares of the company’s stock valued at $7,553,000 after buying an additional 33,182 shares in the last quarter. Hedge funds and other institutional investors own 9.42% of the company’s stock.
Sanofi (NYSE:SNY) traded up 0.05% on Friday, reaching $37.75. 2,760,827 shares of the company’s stock were exchanged. The firm has a market cap of $97.17 billion, a PE ratio of 21.07 and a beta of 0.98. Sanofi has a 12 month low of $37.20 and a 12 month high of $51.88. The firm’s 50-day moving average is $38.67 and its 200-day moving average is $40.40.
SNY has been the topic of several research analyst reports. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “sell” rating in a report on Wednesday, August 3rd. TheStreet cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Monday, August 22nd. Leerink Swann restated a “buy” rating on shares of Sanofi in a report on Sunday, October 9th. Berenberg Bank upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Thursday, September 8th. Finally, Piper Jaffray Cos. initiated coverage on shares of Sanofi in a report on Friday, September 23rd. They set a “neutral” rating on the stock. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company. Sanofi has a consensus rating of “Hold” and a consensus target price of $60.50.
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.